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Epidermal growth factor receptor tyrosine kinase inhibition is
not protective in PCK rats.
Background. Advances in the understanding of cystogenesis,
identification of the PKHD1 gene and availability of a rat model
(the PCK rat) caused by a Pkhd1 mutation facilitate testing
of therapies for autosomal-recessive polycystic kidney disease
(ARPKD). Considerable support exists for the importance of
the epidermal growth factor (EGF)/transforming growth factor-
alpha (TGF-a)/EGF receptor (EGFR) axis and of the adeny-
lyl cyclase-adenosine 3′,5′-cyclic monophosphate (cAMP)
pathway in the pathogenesis of cyst formation and progressive
enlargement.
Methods. To determine whether EGFR tyrosine kinase in-
hibition is protective in the PCK rat, male and female animals
were treated with EKI-785 or EKB-569 or with vehicle alone
between 3 and 10 weeks of age. Biochemical and histomor-
phometric analysis, immunohistochemistry, immunoblotting,
enzyme immunoassay, and quantitative reverse transcription-
polymerase chain reaction (RT-PCR) were used to ascertain
the effects of treatment.
Results. Contrary to other murine models of ARPKD, over-
expression and apical mislocalization of EGFR were not de-
tected in the PCK rats. Consistent with these expression results,
EKI-785 or EKB-569 administration had no effect or worsened
PKD, and had no effect on the development of fibrocystic liver
disease. Increased renal cAMP and vasopressin V2 receptor
expression were observed in the EKI-785–treated animals.
Conclusion. EGFR tyrosine kinase inhibition did not pro-
tect PCK rats from the development of PKD. This may be due
to effects on collecting duct cAMP that counteract possible
beneficial effects on the extracellular-regulated protein kinase
(ERK)/mitogen-activated protein kinase (MAPK) pathway,
particularly in the absence of EGFR overexpression or mislo-
calization. The relevance of these observations to the treatment
of human cystic kidney diseases deserves further study.
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Autosomal-recessive polycystic kidney disease
(ARPKD) is an important childhood nephropathy that
results in death in 30% of affected infants and end-stage
renal disease (ESRD) during the first decade of life in
50% of affected individuals who survive the neonatal
period [1–4]. It is accompanied by biliary dysgenesis,
which is often the major clinical feature in older patients
[1–4]. It is characterized by fusiform dilation of the
collecting ducts in the kidney and by proliferation and
dilatation of the interlobular bile ducts and portal fibrosis
in the liver. Only symptomatic treatment is currently
available. Advances in understanding of cystogenesis
[5–8], identification of the PKHD1 gene [9, 10], and
availability of an animal model orthologous to human
ARPKD [11, 12] may facilitate the development of
therapies. Increasing evidence supports the importance
of the epidermal growth factor (EGF)/transforming
growth factor-alpha (TGF-a)/EGF receptor (EGFR)
axis [13–17] and of the adenylyl cyclase-adenosine
3′,5′-cyclic monophosphate (cAMP) [18–23] pathway
in promoting renal tubular epithelial cell proliferation
and cyst formation. Consequently, interventions aimed
at blocking these pathways have been tested in animal
models of polycystic kidney disease (PKD). Adminis-
tration of a vasopressin V2 receptor antagonist lowered
renal cAMP and markedly inhibited cystogenesis in
three models of slowly progressive PKD (pcy mouse,
orthologous to adolescent nephronophthisis; PCK rat,
orthologous to human ARPKD, and Pkd2WS25/− mouse,
orthologous to human ADPKD) [24, 25] and is also
effective in the cpk mouse, a model of rapidly progressive
PKD [26]. Genetic and/or pharmacologic inhibition of
EGFR tyrosine kinase activity markedly inhibited cystic
disease development [14, 17] in bpk and orpk mice,
two models of autosomal-recessive, rapidly progressive
renal cystic disease, and in Han:SPRD rats [27], a model
of autosomal-dominant slowly progressive renal cystic
disease. Finally, administration of an inhibitor of the
tumor necrosis factor-a (TNF-a) converting enzyme, a
metalloproteinase that cleaves and releases the EGFR
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ligand TGF-a, reduced the severity of cystic disease in
bpk mice [28], particularly if combined with inhibition of
EGFR tyrosine kinase activity [29]. The purpose of this
study was to determine whether EGFR tyrosine kinase
inhibition is effective in the PCK rat, a model of human
ARPKD.
METHODS
EGFR tyrosine kinase inhibition
EKI-785 is a small molecule inhibitor specific for
EGFR tyrosine kinase [30]. This compound binds irre-
versibly to the ATP binding site of EGFR, inhibits the
kinase activity of this protein, blocks EGFR autophos-
phorylation, inhibits cell proliferation, and blocks the
growth of tumors that overexpress EGFR. It also in-
hibits Erb-B2 activity. The duration of EKI-785 activity
is dependent on the half-life of the compound and the
turnover rate of EKI-785–bound EGFR in the plasma
membrane. Preliminary experiments demonstrated that
administration of EKI-785 intraperitoneally every 3 days
resulted in optimal inhibition with minimal toxicity. EKB-
569 is a derivative of EKI-785 with improved pharmacoki-
netics and enteral bioavailability compared to the parent
compound [31].
Experimental animals and study design
Male and female PCK rats maintained at the animal
facilities of the Mayo Clinic, Rochester, Minnesota, were
used for three experimental protocols.
Intraperitoneal administration of EKI-785. At 3 weeks
of age, male PCK littermates and wild-type Sprague-
Dawley rats were divided into two groups. One group
was injected intraperitoneally with 90 mg/kg of EKI-785
every 3 days, between 3 and 10 weeks of age. This dosage
was based on previous pharmacodynamic studies of this
compound in other rat strains. The other group of animals
received vehicle alone (2% Tween 80 and 0.5% methyl-
cellulose in water). The rats were given a standard rat
laboratory diet and water ad libitum.
Intraperitoneal administration of EKB-569. At
3 weeks of age, male and female PCK littermates and
wild-type Sprague-Dawley rats were divided into two
groups. One group was injected intraperitoneally with
20 mg/kg of EKB-569 every 3 days between 3 and 10
weeks of age. This dosage was based on previous pharma-
codynamic studies of this compound in other rat strains.
The other group of animals was injected with vehicle
alone (2% Tween 80 and 0.5% methylcellulose). The rats
were given a standard rat laboratory diet and water ad
libitum.
Enteral administration of EKB-569. At 3 weeks of age
male and female PCK littermates and wild-type Sprague-
Dawley rats were divided into one control and three ex-
perimental groups. The experimental groups were admin-
istered 5, 10, or 20 mg/kg of EKB-569 by gavage daily,
using a 24 gauge, 1 inch, stainless steel fitting tube with
1.25 mm bulb tip between 3 and 10 weeks of age. The
control group received vehicle (2% Tween 80 and 0.5%
methylcellulose) alone. The rats were maintained on a
standard laboratory rat diet and water ad libitum.
Experimental protocol
At 10 weeks of age, the animals were weighed and anes-
thetized with ketamine 60 mg/kg and xylazine 10 mg/
kg, intraperitoneally. Blood was obtained by cardiac
puncture for determination of serum creatinine and
blood urea nitrogen (BUN) levels. The right kidney, liver,
and spleen were placed into preweighed vials containing
4% paraformaldehyde or 10% formaldehyde in phos-
phate buffer (pH 7.4). The tissues were embedded in
ImmunobedTM plastic embedding medium (Polysciences,
Worthington, PA, USA) or in paraffin for histologic stud-
ies. The left kidney was immediately frozen in liquid ni-
trogen for Western blotting analysis and determination
of tyrosine kinase activity.
Histomorphometric analysis and immunohistology
For light microscopy, 5 lm transverse tissue sections,
including cortex, medulla, and papilla, were stained with
hematoxylin-eosin and picrosirius red. Whole transverse
tissue sections stained with hematoxylin-eosin were used
to measure cyst volumes. Renal fibrosis was scored using
the picrosirius red staining of collagen fibers. Image anal-
ysis procedures were performed with Meta-Morph soft-
ware (Universal Imaging, West Chester, PA, USA). The
MetaMorph software system includes a light microscope
with a color digital camera (Nikon DXM 1200) and a Pen-
tium IBM-compatible computer (Del OptiPlex). Stained
sections were visualized under a Nikon microscope and
digital images were acquired using a high-resolution
Nikon digital camera and displaced on the monitor. In-
teractively applied techniques of enhancement were used
for a better definition of interested structures and to
exclude fields too damaged to be analyzed. A colored
threshold was applied at a level that separates cysts from
non-cystic tissue and picrosirius red–positive material
from background in order to calculate the volumes of
cysts or fibrosis. The areas of interest were expressed
as a percentage of total tissue. Because of day-to-day
variability in the intensity of staining, the processing for
picrosirius red staining of all tissue sections from the same
experiment was always done at the same time. Immuno-
histochemical staining of EGFR was conducted using
rabbit polyclonal anti-EGFR antibodies (Cell Signaling
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Fig. 1. Epidermal growth factor receptor (EGFR) expression analyzed by Western analysis and immunolocalization. (A) Immunoblot of proteins
isolated from wild-type and PCK kidneys showing a lower EGFR expression in the cystic kidney. (B) Localization, mostly basolateral, of EGFR in
tubules and cysts from PCK kidney.
Technology, Beverly, MA, USA) (catalog number 2232),
as previously described [15].
Western blotting analysis
Protein was isolated from whole kidneys by homog-
enization in radioimmunoprecipitation assay (RIPA)
buffer with protease inhibitors (complete minitablet;
Roche Diagnostics, Mannheim, Germany). For West-
ern blotting, 30 lg of total protein lysate were di-
luted in sodium dodecyl sulfate (SDS)–reducing buffer
(62.5 mmol/L Tris-HCl, pH 6.8; 25% vol/vol glycerol;
2% wt/vol SDS; 0.01% wt/vol bromophenol blue; and
5% vol/vol p-mercaptoethanol) and subjected to SDS-
polyacrylamide gel electrophoresis (SDS-PAGE) using a
12% separating gel. Samples were transferred to a nitro-
cellulose membrane, treated with blocking buffer (5%
dry milk and 0.05% Tween 20) and probed with rab-
bit polyclonal anti-EGFR antibody. Membranes were
washed, probed with peroxidase-conjugated antirabbit
immunoglobulin, treated with enhanced chemilumines-
cence (ECL) reagent (Amersham Pharmacia Biotech,
Piscataway, NJ, USA) and exposed to autoradiography
film.
cAMP content of whole kidneys
Half kidneys rapidly frozen in liquid nitrogen were
ground to a fine powder under liquid nitrogen in a stain-
less steel mortar and homogenized in 10 volumes of cold
5% trichloroacetic acid (TCA) in a glass-Teflon tissue
grinder. After centrifugation at 600g for 10 minutes, the
supernatants were extracted with 3 volumes of water-
saturated ether. After drying the aqueous extracts, the re-
constituted samples were processed without acetylation
using the enzyme immunoassay kit from Sigma (Sigma-
Aldrich, Inc., St. Louis MO, USA). The results were ex-
pressed in pmol/mg of wet tissue [32].
V2 receptor mRNA expression analysis by real-time
quantitative reverse transcription-polymerase chain
reaction (RT-PCR)
Total RNA was extracted from rat kidney tissues using
TRIzol reagent (Invitrogen, Carlsbad, CA, USA). Four
micrograms of total RNA were reverse transcribed using
SuperScript First-Strand Synthesis System in a total vol-
ume of 50 lL (Invitrogen) at 37◦C for 1 hour to synthesize
cDNA. The amount of V2 mRNA per kidney specimen
was quantified using the real-time PCR SYBR Green as-
say. The 50 lL PCR reaction contained 2 lL of diluted (50-
fold) cDNA, 1× SRBRGreen JumpStart Tag ReadyMix
(Sigma), and 200 nmol/L V2 and ribosomal protein
L32-specific forward and reverse primers(V2 forward
5′-TCGTGCCTGTCAGGTTCTTATC-3′; V2 reverse
5′-TCGGATGGCCCTGGC-3′; ribosomal protein L32
forward 5′-GAAACTGGCGGAAACCCA-3′; and ribo-
somal protein L32 reverse 5′-GGATCTGGCCCTTG
AATCTTC-3′) [33]. PCR reactions were performed in
the DNA Engine Opticon System (MJ Research, Carls-
bad, CA, USA) with 40 cycles at 95◦C for 40 seconds and
60◦C for 1 minute. All data were represented as relative
to the ribosomal protein L32 level.
Statistical analysis
Comparisons between groups were made using one-
way or two-way analysis of variance (ANOVA) with least
significant difference comparisons of the means or Stu-
dent t test as appropriate.
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Table 1. Intraperitoneal administration of EKI-785 to male wild-type and PCK rats
Sprague-Dawley+/+ PCK
EKI-785 (mg/kg body weight) Control (N = 11) 90 (N = 7) P value Control (N = 7) 90 (N = 7) P value
Body weight g 332.6 ± 22.1 321.7 ± 27.6 0.427 364.6 ± 36.0 317.9 ± 18.3 0.107
Kidney weight % body weight 0.82 ± 0.04 0.85 ± 0.03 0.090 1.46 ± 0.30 2.79 ± 0.09 0.005
Liver weight % body weight 4.23 ± 0.17 4.42 ± 0.29 0.115 5.47 ± 0.42 6.17 ± 0.47 0.019
Spleen weight % body weight 0.38 ± 0.09 0.55 ± 0.15 0.013 0.32 ± 0.03 0.59 ± 0.15 0.001
Serum creatinine mg/dL 0.42 ± 0.04 0.40 ± 0.00 0.233 040 ± 0.00 0.51 ± 0.08 0.006
Serum blood urea nitrogen mg/dL 20.3 ± 2.5 22.7 ± 4.1 0.177 17.7 ± 1.8 30.6 ± 7.4 0.001
Kidney cyst volume % 20.8 ± 5.8 35.7 ± 5.8 0.001
Kidney fibrosis score % 2.39 ± 0.32 4.51 ± 1.54 0.001
Liver cyst volume % 6.02 ± 0.93 4.89 ± 1.11 0.077
Liver fibrosis score % 5.63 ± 0.83 5.09 ± 1.69 0.503
RESULTS
Renal expression of EGFR in PCK rats
The total EGFR levels measured by Western analysis
were reduced in PCK rats as compared to the wild-type
Sprague-Dawley rats (Fig. 1A). Consistent with these re-
sults, the EGFR staining of the kidneys in the PCK rats
was weak and predominantly basolateral (Fig. 1B).
Intraperitoneal administration of EKI-785 and EKB-569
The intraperitoneal administration of EKI-785 signifi-
cantly worsened the development of renal cystic disease,
as reflected by higher kidney weights, concentrations
of serum creatinine and BUN, cyst volumes and fibro-
sis scores (Table 1) (Fig. 2). It also caused a significant
increase in the weights of the liver and spleen, with-
out increasing the severity of the fibrocystic liver disease
as reflected by similar hepatic cyst volumes and fibro-
sis scores in the EKI-785–treated and control rats. The
higher weight of the spleens in the treated rats was un-
related to the fibrocystic liver disease, since it was also
observed in the wild-type animals treated with EKI-785.
The intraperitoneal administration of EKB-569 to male
and female PCK rats had similar effects to that of EKI-
785 to male rats (Table 2). Independent of treatment, the
female PCK rats had more severe fibrocystic liver disease
than their male counterparts (Table 2).
Enteral administration of EKB-569
The administration of EKB-569 by gavage at a dose
of 20 mg/kg body weight every day resulted in a slight
increase in the renal cyst volume without a significant
change in kidney weight (Table 3). Lower doses did not
have a significant effect on the kidneys. The administra-
tion of EKB-569 at doses of 10 or 20 mg/kg body weight
every day resulted in significantly higher liver and spleen
weights without an aggravation of the fibropolycystic liver
disease as reflected by the histopathologic scores.
A B
C D
E F
Fig. 2. Representative cross-sections (hematoxylin-eosin) of kidneys
from control PCK rats (A, C, and E) and PCK rats treated with in-
traperitoneal EKI-785 (B) or EKB-569 (D and F). Kidneys (A to D)
are from male animals, and kidneys (E and F) are from female animals.
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Table 2. Intraperitoneal administration of EKB-569 to PCK rats
Male Female P valueEKB-569
mg/kg body weight Control (N = 9) 20 (N = 5) Control (N = 8) 20 (N = 5) Gender EKB20
Body weight g 299.4 ± 33.9 290.0 ± 6.7 214.3 ± 25.9 197.0 ± 8.3 <0.001 0.193
Kidney weight % body weight 1.52 ± 0.22 1.60 ± 0.10 1.27 ± 0.14 1.69 ± 0.33 0.346 0.006
Liver weight % body weight 4.52 ± 0.31 4.99 ± 0.26 5.30 ± 0.64 5.90 ± 0.69 <0.001 0.014
Spleen weight % body weight 0.34 ± 0.03 0.46 ± 0.07 0.38 ± 0.05 0.52 ± 0.08 <0.001 0.033
Serum creatinine mg/dL 0.50 ± 0.00 0.62 ± 0.28 0.50 ± 0.00 0.44 ± 0.05 0.070 0.532
Serum blood urea nitrogen mg/dL 17.9 ± 4.1 22.2 ± 7.6 15.6 ± 2.3 33.2 ± 22.5 0.299 0.013
Kidney cyst volume % 22.6 ± 8.1 24.3 ± 5.2 21.6 ± 3.3 27.9 ± 3.6 0.526 0.018
Kidney fibrosis score % 1.07 ± 0.46 1.73 ± 0.80 1.09 ± 0.49 1.93 ± 0.55 0.625 0.003
Liver cyst volume % 6.45 ± 1.40 4.89 ± 0.96 6.52 ± 1.25 7.74 ± 1.31 0.009 0.740
Liver fibrosis score % 7.30 ± 1.49 7.56 ± 1.95 7.94 ± 1.81 8.96 ± 1.25 0.133 0.339
Renal levels of cAMP and expression of V2 receptors
The renal concentrations of cAMP were significantly
higher in the PCK than in the wild-type rats (Fig. 3) (P <
0.001). Since cAMP is mostly intracellular and its con-
centration in cyst fluid is very low [32], the cAMP accu-
mulation in total kidney tissue likely underestimates that
in the noncystic parenchyma. The intraperitoneal admin-
istration of EKI-785 to PCK rats was accompanied by a
significantly higher renal accumulation of cAMP, as well
as by a higher expression of the vasopressin V2 receptor
(Fig. 3). The administration of EKB-569 had similar ef-
fects that did not reach statistical significance (P = 0.13
and P = 0.14, respectively).
DISCUSSION
This study shows that two irreversible EGFR tyro-
sine kinase inhibitors provide no protective effect and
may worsen PKD in the PCK rat. This result is con-
trary to a large body of data supporting the importance
of the EGF/TGF-a/EGFR pathway in the pathogene-
sis of PKD. Renal cyst fluids from ADPKD, ARPKD,
and rodent models of PKD contain EGF-like peptides
in mitogenic concentrations [34, 35], although the renal
expression of EGF seems to be down-regulated [36–39].
TGF-a is over-expressed in ADPKD kidneys [40, 41].
EGF and TGF-a are cystogenic in in vitro systems [16,
42, 43]. Transgenic over-expression of TGF-a [44], Erb-
B2 [45] (a member of the EGFR-related tyrosine ki-
nase receptor family) and T24ras [46] (a transduction
molecule in the EGFR signaling pathway) induce cys-
togenesis in mice. EGFR and Erb-B2 [13, 15, 47, 48] are
overexpressed and mislocalized to the apical membrane
of the cystic epithelium in human autosomal-dominant
polycystic disease (ADPKD) and ARPKD and in ro-
dent models of these diseases. The mislocalized receptors
can bind EGF with high affinity, undergo autophospho-
rylation, and initiate a signaling cascade that results in
cell proliferation [15]. Finally, genetic and/or pharmaco-
logic inhibition of EGFR tyrosine kinase activity in vitro
and/or in vivo inhibits the development of cystic disease
in bpk and orpk mice [14, 17, 29] and in Han:SPRD rats
[27].
The detrimental effect of EKI-785 and EKB 569 in this
study is consistent with the low expression and the nor-
mal location of EGFRs in the PCK collecting tubule and
cyst lining epithelial cells. Previous studies have shown
that the mitogenic effect of EGF correlates with EGFR
density [49]. The contrast in EGFR expression between
the PCK rat and human ARPKD or murine models of
human ARPKD remains unexplained. Possibly, the PCK
rat is not a model for severe human ARPKD, despite
being caused by a mutation in the rat ortholog Pkhd1.
Similar to human ARPKD, the PCK rat is characterized
by cysts in the collecting ducts and by bile duct dilatation
and portal fibrosis [11, 12]. Nevertheless, the renal cysts
develop later and predominantly in the outer medulla,
and the degree of portal fibrosis is mild without forma-
tion of fibrous septa between portal tracts. Whether these
differences are due to a hypomorphic mutation in the
PCK rat, that does not completely inactivate the gene, or
to species differences, genetic modifiers or other factors
will require further study. These results may also reflect
the pleiomorphic effects that EGF signaling and its in-
hibition may have in different model systems. Previous
studies have shown that the role of EGF in cystogenesis
may depend on the stage of the development [50], and
that administration of EGF during the neonatal period
(days 1 to 9, a period critical for the differentiation of the
collecting duct) retarded the development of azotemia,
common bile duct dilation, and intrahepatic bile duct pro-
liferation in the bpk mouse [50] and renal cystogenesis
and azotemia in the cpk mouse [51].
Despite the limitations that the PCK rat may have as a
model of severe ARPKD, the observations in this study
may be relevant to the treatment of slowly progressive
forms of PKD. Cross-talk between cellular signal trans-
duction pathways that involve tyrosine phosphorylation,
such as the EGF/TGF-a/EGFR axis, and those mediated
by G proteins, such as G protein coupled receptor induced
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8 accumulation of cAMP, is complex and cell-specific. EGF
and cAMP exert opposing proliferative and antiprolif-
erative effects, respectively, on cultured normal human
kidney cortex (NHK) cells [20]. On the other hand, they
have complementary and additive proliferative effects on
ADPKD cells [22]. It is uncertain whether this synergistic
interaction also occurs in vivo. The results of this study
suggest that EGFR tyrosine kinase inhibition in the PCK
rat may have the unexpected effect of increasing the renal
accumulation of cAMP.
The increased levels of cAMP and the up-regulation of
the vasopressin V2 receptors in the kidneys of EKI-785–
treated PCK rats and the detrimental effect of EGFR
tyrosine kinase inhibition may be explained by a number
of previous observations. EGFR tyrosine kinase activa-
tion triggers numerous downstream signaling pathways,
including phosphorylation of G proteins, activation of
phospholipase C, and downstream calcium and protein
kinase C (PKC)-mediated cascades, and stimulation of
the ERK pathway [52]. Purified EGFR can phosphory-
late Gsa in vitro [53] and in vivo [54] and directly stim-
ulate of adenylyl cyclase; at the same time, it prevents
Gsa activation by G protein–coupled receptors, such as
the bradykinin receptor, and reduces cAMP accumula-
tion [54]. An increase in intracellular Ca2+, such as oc-
curs following EGFR activation, can stimulate cAMP
phosphodiesterases, inhibit adenylyl cyclases, and inhibit
vasopressin-induced renal accumulation of cAMP [55].
EGFR activation induces the generation of prostaglandin
E2 (PGE2) in the collecting ducts and PGE2 inhibits
vasopressin-induced cAMP accumulation predominantly
through stimulation of calcium-dependent phosphodi-
esterases and to a lesser extent by inhibition of the cal-
cium inhibitable adenylate cyclase type 6 [56, 57]. EGF
has been reported to down-regulate the expression of va-
sopressin V2 receptors in vivo [26] and to inhibit the hy-
drosmotic effect of vasopressin in isolated perfused rabbit
cortical collecting tubules by a mechanism linked to PKC
activation [58]. Finally, a number of tyrosine kinase in-
hibitors, such as genistein, erbstatin, tyrphostin B44, and
herbimycin, have been reported to potentiate adrenergic
or forskolin-induced cAMP accumulation in rat pinealo-
cytes probably through inhibition of a cAMP phosphodi-
esterase [59].
CONCLUSION
The administration of EGFR tyrosine kinase inhibitors
had unexpected effects on the development of PKD in the
PCK rat, possibily due to stimulation of cAMP accumu-
lation in collecting ducts with attendant proliferation and
Cl−/fluid secretion. The relevance of these observations
to the treatment of human ARPKD or ADPKD remains
uncertain and deserves further study.
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Fig. 3. Renal levels of adenosine 3′,5′-cyclic
monophosphate (cAMP) and vasopressin V2
receptor mRNA in male control PCK rats and
rats treated intraperitoneally with EKI-785 or
EKB-569. ∗Significant difference (P < 0.05)
compared to control.
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